60756-05-0

Basic information

• Product Name: cyclopentyl chlorothiolformate
• Synonyms: cyclopentyl chlorothiolformate
• CAS NO: 60756-05-0
• Molecular Weight: 164.656
• Mol File: 60756-05-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: cyclopentyl chlorothiolformate(CAS DataBase Reference)
• NIST Chemistry Reference: cyclopentyl chlorothiolformate(60756-05-0)
• EPA Substance Registry System: cyclopentyl chlorothiolformate(60756-05-0)

Safety Data

• Hazardous Substances Data: 60756-05-0(Hazardous Substances Data)

Upstream product

• 100-53-8 phenylmethanethiol 

Downstream Products

• 214286-98-3 ethyl-3--L-Phe-L-(Tr-Gln)>-E-propenoate 
• 214286-83-6 ethyl-3--L-Phe(4-F)-L-(Tr-Gln)>-E-propenoate 
• 214286-77-8 (E)-(S)-4-[(2R,5S)-5-Cyclopentylsulfanylcarbonylamino-6-methyl-4-oxo-2-(4-trifluoromethyl-benzyl)-heptanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-59-6 (E)-(S)-4-[(2R,5S)-5-Cyclopentylsulfanylcarbonylamino-2-(4-methyl-benzyl)-4-oxo-6-phenyl-hexanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-87-0 (E)-(S)-4-[(2R,5S)-5-Cyclopentylsulfanylcarbonylamino-2-(4-fluoro-benzyl)-7-methyl-4-oxo-octanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-92-7 (E)-(S)-4-[(2R,5S)-5-Cyclopentylsulfanylcarbonylamino-7-methyl-2-(4-methyl-benzyl)-4-oxo-octanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-70-1 ethyl-3--L-Phe(4-F)-L-(Tr-Gln)>-E-propenoate 
• 214286-37-0 (E)-(S)-4-((2R,5S)-2-Benzyl-5-cyclopentylsulfanylcarbonylamino-7-methyl-4-oxo-octanoylamino)-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-46-1 (E)-(S)-4-((2R,5S)-2-Benzyl-5-cyclopentylsulfanylcarbonylamino-6-methyl-4-oxo-heptanoylamino)-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 

Relevant articles and documents

Antipicornaviral compounds and methods for their use and preparation

Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.